Skip to main content
SpringerLink
Log in

Long Circulating Liposomes: Old Drugs, New Therapeutics

  • Book
  • © 1998

Overview

Editors:
  1. Martin C. Woodle

    1. Genetic Therapy, Inc., Gaithersburg, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Gerrit Storm

    1. Department of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Biotechnology Intelligence Unit (BIOIU)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 16.99 USD 84.99
Discount applied Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (20 chapters)

  1. Current Medical Applications

    1. Diagnostics

      1. Tumor Imaging with Long Circulating Liposomes
        • Naoto Oku
        Pages 257-266

  2. Future Medical Applications: Surface Ligands and Targeting

    1. Front Matter

      Pages 267-267
      Download chapter PDF

    2. Antibody-Mediated Targeting of PEG-Coated Liposomes

      • Alexander L. Klibanov
      Pages 269-286

    3. Small Molecule Ligands for Targeting Long Circulating Liposomes

      • Martin C. Woodle, Danilo D. Lasic, Gerrit Storm
      Pages 287-295

  3. Back Matter

    Pages 297-301
    Download chapter PDF
Back to top

Keywords

About this book

This book provides an up-to-date evaluation of clinical aspects of newly available "long-circulating liposome" formulations. Based on results from numerous clinical studies, the book describes the fundamentals of this new technology, discusses how it may influence the pharmacology of existing well-known agents reformulated in this manner, and elaborates on future expectations. It provides the practicing clinician - in particular, oncologists and critical care infectious disease physicians - with the tools needed to use these new formulations towards the best outcome for the patient.

Editors and Affiliations

  • Genetic Therapy, Inc., Gaithersburg, USA

    Martin C. Woodle

  • Department of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands

    Gerrit Storm

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation